allopur 300 mg
orifarm healthcare a/s - allopurinol - tablett - 300 mg
allopur 100 mg
orifarm healthcare a/s - allopurinol - tablett - 100 mg
allopurinol orion 300 mg
orion corporation - espoo - allopurinol - tablett - 300 mg
allopurinol orion 100 mg
orion corporation - espoo - allopurinol - tablett - 100 mg
allopurinol sandoz 100 mg
sandoz - københavn - allopurinol - tablett - 100 mg
allopurinol sandoz 300 mg
sandoz - københavn - allopurinol - tablett - 300 mg
allopurinol aristo 300 mg
aristo pharma gmbh - allopurinol - tablett - 300 mg
allopurinol aristo 100 mg
aristo pharma gmbh - allopurinol - tablett - 100 mg
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
duzallo
grunenthal gmbh - allopurinol, lesinurad - gikt - antigout preparater - duzallo er angitt i voksne for behandling av hyperuricaemia i gikt pasienter som ikke har oppnådd målet serum urinsyre med en tilstrekkelig dose av allopurinol alene.